[#item_full_content] A report stating that the administration is close to reclassifying cannabis as a Schedule III drug has the $32 billion industry hotly anticipating reform.
Read More
[#item_full_content] A report stating that the administration is close to reclassifying cannabis as a Schedule III drug has the $32 billion industry hotly anticipating reform.
Read More